Investigating the role of the Liver X Receptor in Potentiating Mitotane Therapy in Adrenocortical Carcinoma
View / Open Files
Authors
Warde, K
Donlon, PT
Schoenmakers, E
Gurnell, M
Dennedy, MC
Publication Date
2018Journal Title
IRISH JOURNAL OF MEDICAL SCIENCE
Conference Name
Irish Endocrine Society
ISSN
0021-1265
Volume
187
Pages
S182-S182
Type
Conference Object
Metadata
Show full item recordCitation
Warde, K., Donlon, P., Schoenmakers, E., Gurnell, M., & Dennedy, M. (2018). Investigating the role of the Liver X Receptor in Potentiating Mitotane Therapy in Adrenocortical Carcinoma. IRISH JOURNAL OF MEDICAL SCIENCE, 187 S182-S182. https://doi.org/10.17863/CAM.33136
Abstract
Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy. Adjuvant mitotane improves survival but is limited by its narrow therapeutic window and escape from therapeutic efficacy. Mitotane modulates its adrenolytic effect through SOAT1 antagonism and consequent free cholesterol accumulation. Liver X receptors (LXRs), are highly expressed in adrenal tissue and mediate cholesterol homeostasis. We hypothesise that selective antagonism of LXRα increases toxic lipid accumulation in adrenocortical cells and potentiates the adrenolytic effect of mitotane.
Sponsorship
Wellcome Trust (095564/Z/11/Z)
Identifiers
External DOI: https://doi.org/10.17863/CAM.33136
This record's URL: https://www.repository.cam.ac.uk/handle/1810/285792
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.